Healthcare & Life Sciences
VedaCorp advises Intron Lifesciences, a leading animal probiotics company, on its strategic investment from Param Capital
About
Intron Lifesciences Private Limited
Intron Lifesciences Private Limited, incorporated in 2010 and located in Hyderabad, is an animal supplement nutrition company in India with end-to-end manufacturing capabilities. The Company manufactures feed supplements for poultry, aquaculture, and ruminants.
InvAscent
InvAscent, is one of India’s leading mid-market focused private equity funds, investing across the healthcare and life sciences sectors. They typically provide growth capital to high potential companies and adopts a collaborative, partnership-driven approach to ensure long term value creation.
Param Capital
Param Capital, is a privately owned investment firm founded by Mukul Agrawal, focusing on long term investments in listed companies and high potential private businesses. This transaction marks Param Capital’s first majority stake investment.
Background
We are pleased to announce that our clients Intron Lifesciences Private Limited (“Intron”) has raised strategic investment from Param Capital Research Private Limited (“Param”). As part of the transaction, InvAscent ,a healthcare and life science focused fund, has exited its entire stake in the Company to Param.
Intron, incorporated in 2018 and headquartered in Hyderabad, is engaged in the business of manufacturing probiotics and other biotech products aimed at enhancing animal health and nutrition. It offers a comprehensive portfolio of R&D-backed feed supplements for poultry, aquaculture, and ruminants. Intron’s branded formulations are supplied to customers across the globe.
This investment marks Param Capital’s maiden investment into the rapidly growing animal health industry.
Veda Corporate Advisors (“VedaCorp”) was the exclusive financial advisor to the Company and its shareholders. VedaCorp provided comprehensive transaction advisory services covering identification of prospective investors, strategic positioning including deal structuring, negotiation of key commercial terms, leading to the successful closure of the transaction.
This marks VedaCorp’s 3rd win in the dynamic animal health space and 62nd deal overall in the healthcare and life sciences space. This also demonstrates Vedacorp’s ability to deliver exit for investors and partner with strategic family offices to deliver successful outcomes.